Literature DB >> 30318938

The emergence of dihydroorotate dehydrogenase (DHODH) as a therapeutic target in acute myeloid leukemia.

David B Sykes1.   

Abstract

Entities:  

Keywords:  Acute myeloid leukemia; Brequinar; DHODH; differentiation; metabolism; nucleotides; pyrimidines; therapeutic window

Mesh：

Substances：

Year:  2018        PMID： 30318938      PMCID： PMC6457988          DOI： 10.1080/14728222.2018.1536748

Source DB:  PubMed          Journal:  Expert Opin Ther Targets        ISSN： 1472-8222            Impact factor:   6.902


× No keyword cloud information.
  19 in total

1.  A77 1726 induces differentiation of human myeloid leukemia K562 cells by depletion of intracellular CTP pools.

Authors:  Min Huang; Yanhong Wang; Matthew Collins; Beverly S Mitchell; Lee M Graves
Journal:  Mol Pharmacol       Date:  2002-09       Impact factor: 4.436

2.  Multicenter phase II trial of brequinar sodium in patients with advanced melanoma.

Authors:  R Natale; R Wheeler; M Moore; B Dallaire; W Lynch; R Carlson; A Grillo-Lopez; J Gyves
Journal:  Ann Oncol       Date:  1992-09       Impact factor: 32.976

3.  Multicenter phase II trial of brequinar sodium in patients with advanced squamous-cell carcinoma of the head and neck.

Authors:  S Urba; J Doroshow; C Cripps; F Robert; E Velez-Garcia; B Dallaire; D Adams; R Carlson; A Grillo-Lopez; J Gyves
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

4.  Pharmacokinetics of Brequinar sodium (NSC 368390) in patients with solid tumors during a phase I study.

Authors:  G Schwartsmann; W J van der Vijgh; M B van Hennik; I Klein; J B Vermorken; P Dodion; W W ten Bokkel Huinink; G Joggi; H Gall; N Crespeigne
Journal:  Eur J Cancer Clin Oncol       Date:  1989-12

5.  In vivo inhibition of the pyrimidine de novo enzyme dihydroorotic acid dehydrogenase by brequinar sodium (DUP-785; NSC 368390) in mice and patients.

Authors:  G J Peters; G Schwartsmann; J C Nadal; E J Laurensse; C J van Groeningen; W J van der Vijgh; H M Pinedo
Journal:  Cancer Res       Date:  1990-08-01       Impact factor: 12.701

6.  A phase I clinical and pharmacokinetic study of Brequinar sodium, DUP 785 (NSC 368390), using a weekly and a biweekly schedule.

Authors:  E Bork; S Vest; H H Hansen
Journal:  Eur J Cancer Clin Oncol       Date:  1989-10

7.  Dihydroorotate dehydrogenase inhibitor A771726 (leflunomide) induces apoptosis and diminishes proliferation of multiple myeloma cells.

Authors:  Philipp Baumann; Sonja Mandl-Weber; Andreas Völkl; Christian Adam; Irmgard Bumeder; Fuat Oduncu; Ralf Schmidmaier
Journal:  Mol Cancer Ther       Date:  2009-01-27       Impact factor: 6.261

Review 8.  The human concentrative and equilibrative nucleoside transporter families, SLC28 and SLC29.

Authors:  James D Young; Sylvia Y M Yao; Jocelyn M Baldwin; Carol E Cass; Stephen A Baldwin
Journal:  Mol Aspects Med       Date:  2013 Apr-Jun

9.  DHODH modulates transcriptional elongation in the neural crest and melanoma.

Authors:  Richard Mark White; Jennifer Cech; Sutheera Ratanasirintrawoot; Charles Y Lin; Peter B Rahl; Christopher J Burke; Erin Langdon; Matthew L Tomlinson; Jack Mosher; Charles Kaufman; Frank Chen; Hannah K Long; Martin Kramer; Sumon Datta; Donna Neuberg; Scott Granter; Richard A Young; Sean Morrison; Grant N Wheeler; Leonard I Zon
Journal:  Nature       Date:  2011-03-24       Impact factor: 49.962

10.  Exome sequencing identifies the cause of a mendelian disorder.

Authors:  Sarah B Ng; Kati J Buckingham; Choli Lee; Abigail W Bigham; Holly K Tabor; Karin M Dent; Chad D Huff; Paul T Shannon; Ethylin Wang Jabs; Deborah A Nickerson; Jay Shendure; Michael J Bamshad
Journal:  Nat Genet       Date:  2009-11-13       Impact factor: 38.330
View more
  28 in total

1.  Untargeted LC-MS metabolomic studies of Asteraceae species to discover inhibitors of Leishmania major dihydroorotate dehydrogenase.

Authors:  Lucas A Chibli; Annylory L Rosa; Maria Cristina Nonato; Fernando B Da Costa
Journal:  Metabolomics       Date:  2019-04-04       Impact factor: 4.290

Review 2.  Mitochondrial Metabolism as a Target for Cancer Therapy.

Authors:  Karthik Vasan; Marie Werner; Navdeep S Chandel
Journal:  Cell Metab       Date:  2020-07-14       Impact factor: 27.287

Review 3.  Active mitochondrial respiration in cancer: a target for the drug.

Authors:  Minakshi Bedi; Manju Ray; Alok Ghosh
Journal:  Mol Cell Biochem       Date:  2021-10-30       Impact factor: 3.396

4.  Identification of DHODH as a therapeutic target in small cell lung cancer.

Authors:  Leanne Li; Sheng Rong Ng; Caterina I Colón; Benjamin J Drapkin; Peggy P Hsu; Zhaoqi Li; Christopher S Nabel; Caroline A Lewis; Rodrigo Romero; Kim L Mercer; Arjun Bhutkar; Sarah Phat; David T Myers; Mandar Deepak Muzumdar; Peter M K Westcott; Mary Clare Beytagh; Anna F Farago; Matthew G Vander Heiden; Nicholas J Dyson; Tyler Jacks
Journal:  Sci Transl Med       Date:  2019-11-06       Impact factor: 17.956

Review 5.  Mitochondria as Signaling Organelles Control Mammalian Stem Cell Fate.

Authors:  Ram Prosad Chakrabarty; Navdeep S Chandel
Journal:  Cell Stem Cell       Date:  2021-03-04       Impact factor: 24.633

Review 6.  DHODH and cancer: promising prospects to be explored.

Authors:  Yue Zhou; Lei Tao; Xia Zhou; Zeping Zuo; Jin Gong; Xiaocong Liu; Yang Zhou; Chunqi Liu; Na Sang; Huan Liu; Jiao Zou; Kun Gou; Xiaowei Yang; Yinglan Zhao
Journal:  Cancer Metab       Date:  2021-05-10

Review 7.  Metabolomics in cancer research and emerging applications in clinical oncology.

Authors:  Daniel R Schmidt; Rutulkumar Patel; David G Kirsch; Caroline A Lewis; Matthew G Vander Heiden; Jason W Locasale
Journal:  CA Cancer J Clin       Date:  2021-05-13       Impact factor: 286.130

8.  Inhibition of pyrimidine biosynthesis targets protein translation in acute myeloid leukemia.

Authors:  Joan So; Alexander C Lewis; Lorey K Smith; Kym Stanley; Rheana Franich; David Yoannidis; Lizzy Pijpers; Pilar Dominguez; Simon J Hogg; Stephin J Vervoort; Fiona C Brown; Ricky W Johnstone; Gabrielle McDonald; Danielle B Ulanet; Josh Murtie; Emily Gruber; Lev M Kats
Journal:  EMBO Mol Med       Date:  2022-05-06       Impact factor: 14.260

Review 9.  Dysregulated haematopoietic stem cell behaviour in myeloid leukaemogenesis.

Authors:  Masayuki Yamashita; Paul V Dellorusso; Oakley C Olson; Emmanuelle Passegué
Journal:  Nat Rev Cancer       Date:  2020-05-15       Impact factor: 60.716

Review 10.  Targeting nucleotide metabolism as the nexus of viral infections, cancer, and the immune response.

Authors:  Yarden Ariav; James H Ch'ng; Heather R Christofk; Noga Ron-Harel; Ayelet Erez
Journal:  Sci Adv       Date:  2021-05-19       Impact factor: 14.136
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.